

**POLICY NAME**

Pyrukynd (mitapivat)

**POLICY #**

3167P

## Criteria

### Exclusion Criteria – Any of the following prevents coverage

- ☐ 2.1 Patients homozygous for the R479H mutation
- ☐ 2.2 Patients with 2 non-missense mutations in PKLR, without another missense mutation (these patients did not demonstrate benefit from therapy in clinical trials)

### Hemolytic Anemia related to Pyruvate Kinase Deficiency (PKD)

- ☐ 1.1 Diagnosis of hemolytic anemia related to Pyruvate Kinase Deficiency (PKD) as evidenced by genetic testing
  - Genetic testing must support at least two mutant alleles of the PKLR gene of which at least one is a missense mutation
- ☐ 1.2 Age 18 years or older
- ☐ 1.3 Prescribed by or in consultation with a hematologist (blood disorder doctor) or specialist in hemolytic anemia
- ☐ 1.4 Patient has required red blood cell transfusions within the last year
- ☐ 1.5 Hemoglobin level  $\leq 10$  mg/dL
- ☐ 1.6 Currently taking folic acid 0.8mg daily